Jong Min Oh Selected Research

Monoamine Oxidase (MAO)

1/2024	Machine learning driven web-based app platform for the discovery of monoamine oxidase B inhibitors.
1/2024	Enzyme Inhibition Assays for Monoamine Oxidase.
12/2023	Repurposing Azoles to Resolve Serotogenic Toxicity Associated with Linezolid to Combat Multidrug-Resistant Tuberculosis.
8/2023	Assembling a Cinnamyl Pharmacophore in the C3-Position of Substituted Isatins via Microwave-Assisted Synthesis: Development of a New Class of Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson's Disease.
8/2023	Halogenated class of oximes as a new class of monoamine oxidase-B inhibitors for the treatment of Parkinson's disease: Synthesis, biochemistry, and molecular dynamics study.
2/2023	Development of Isopropyl-Tailed Chalcones as a New Class of Selective MAO-B Inhibitors for the Treatment of Parkinson's Disorder.
1/2023	Exploration of a new class of monoamine oxidase B inhibitors by assembling benzyloxy pharmacophore on halogenated chalcones.
9/2022	Synthesis of 4-substituted benzyl-2-triazole-linked-tryptamine-paeonol derivatives and evaluation of their selective inhibitions against butyrylcholinesterase and monoamine oxidase-B.
3/2022	Conjugated Dienones from Differently Substituted Cinnamaldehyde as Highly Potent Monoamine Oxidase-B Inhibitors: Synthesis, Biochemistry, and Computational Chemistry.
11/2021	Replacement of Chalcone-Ethers with Chalcone-Thioethers as Potent and Highly Selective Monoamine Oxidase-B Inhibitors and Their Protein-Ligand Interactions.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jong Min Oh Research Topics

Disease

8	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2024 - 11/2020
7	Parkinson Disease (Parkinson's Disease) 01/2024 - 08/2021
6	Alzheimer Disease (Alzheimer's Disease) 01/2024 - 11/2020
4	Nervous System Diseases (Neurological Disorders) 11/2021 - 05/2018
3	Neuroblastoma 01/2024 - 08/2023
1	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 01/2024
1	Multidrug-Resistant Tuberculosis (Drug-Resistant Tuberculosis) 12/2023
1	Dementia (Dementias) 09/2022
1	Infections 11/2018

Drug/Important Bio-Agent (IBA)

18	Monoamine Oxidase (MAO)IBA 01/2024 - 05/2018
3	Monoamine Oxidase Inhibitors (Monoamine Oxidase Inhibitor)IBA 01/2024 - 09/2022
3	EnzymesIBA 12/2023 - 05/2018
2	RotenoneIBA 11/2023 - 08/2023
2	Cholinesterases (Cholinesterase)IBA 09/2022 - 08/2021
2	ChalconesIBA 08/2021 - 06/2021
1	Neuroprotective AgentsIBA 01/2024
1	IsatinIBA 01/2024
1	LipopolysaccharidesIBA 01/2024
1	AzolesIBA 12/2023
1	Linezolid (Zyvox)FDA Link 12/2023
1	OximesIBA 08/2023
1	Proteins (Proteins, Gene)FDA Link 08/2021
1	Amyloid (Amyloid Fibrils)IBA 08/2021
1	Oxidoreductases (Dehydrogenase)IBA 08/2021
1	PiperazineIBA 08/2021
1	2-(N-cyclohexylamino)ethanesulfonic acid (CHES)IBA 08/2021
1	Anti-Infective Agents (Microbicides)IBA 11/2018
1	divaricatic acidIBA 11/2018
1	GlycosidesIBA 05/2018
1	tilianinIBA 05/2018
1	flavoneIBA 05/2018
1	acacetinIBA 05/2018

Therapy/Procedure

2	Therapeutics 07/2021 - 01/2021